RE:RE:What NextEF88,
I agree with your points.
Biotech stocks take time to appreicate in value. In addition they have the potential to be 10 and 100 baggers. Some of us have the luxury of time or patience, some may not due to other financial obligations.
If we look at where Gilles wants to take the company, he is delivering, except. on timelines (ie. closure of LEDUC plant painstakingly took years, but it appears customers wanted it open as a contingency plan). A deal has been elusive for reasons we do not know (we all agree shareholder communication could be better). It wasn't too long ago that we said Gilles had too much on his plate to negotiate a deal on his own. We should all take solace that he is seriously looking to ink a deal and hiring a consulting agency is proof of that.
I expect things to accelerate in 2021 year, but can hold on for 2+ years as long as progress is being made.
EbbFlow88 wrote: You're right and no one is disputing your points, but Gilles and Ceapro have given us $6M on the balance sheet with no LT debt and many potential future projects that are close to fruition.
This reminds me of Jonathan Goodman at Paladin/Knight Therapeutics. He goes about his business building a great company patiently and financially prudently. Paladin went from 1.50 to 150 when he sold it.That took about 20 years and most of that 20 years very little happened. Just persistent growth and work behind the scenes. Boring but in the end provided a big win.
That's what I see here.
Sales have increased and so has cash reserves so that provides a big safety net. Then there's the YBG Germany plant/equipment and all the rest. Maybe it takes another 5-10+ years but I have strong conviction this will work out.